Clinical trial
Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and…
NCT00083382 · University of Arkansas, Other · Completed
Key facts
| NCT number | NCT00083382 |
|---|---|
| Title | Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide |
| Official title | UARK 98-036, A Phase II Trial of Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide in Patients With Smoldering/Indolent Myeloma |
| Lead sponsor | University of Arkansas, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Pamidronate, Thalidomide, Zometa |
| Enrollment | 83 |
| Start date | Dec 1, 1998 |
| Primary completion | May 1, 2014 |
| Completion | May 1, 2014 |
| First posted | May 24, 2004 |
| Last update posted | Jun 24, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: